LIC MF Healthcare Fund-Direct Plan-Growth
LIC Mutual Fund Asset Management Limited · Direct Plan · Growth
Fund overview
Nil upto 12% of units and 1% for remaining units on or before 90D, Nil after 90D
Returns & rankings
| Period | Fund Returns | Category Avg. | Rank | VS Category |
|---|---|---|---|---|
| … | ||||
Green = fund outperformed the category average for that period; red = underperformed. Periods under 1 year always show absolute (non-annualised) returns. Past performance does not guarantee future returns.
Return calculator
One-time investment
₹5,000
| Over the past | Total investment | Would've become | Returns |
|---|---|---|---|
| 1 Year | ₹5,000 | ₹5,875 | +875 |
| 3 Years | ₹5,000 | ₹8,111 | +3,111 |
| 5 Years | ₹5,000 | ₹11,197 | +6,197 |
Calculated using the fund's annualised return since inception (17.5% p.a.) as period-wise historical returns aren't available in the current feed. Actual returns fluctuate and are not guaranteed. Mutual fund investments are subject to market risks.
Holdings
25 securitiesTop 10 holdings make up 56.4% of the portfolio.
| Security | Sector | Market Cap | Weight |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals & Biotechnology | Large Cap | 9.59% |
| Divi'S Laboratories Ltd | Pharmaceuticals & Biotechnology | Large Cap | 9.07% |
| Neuland Laboratories Ltd | Pharmaceuticals & Biotechnology | Small Cap | 6.14% |
| Torrent Pharmaceuticals Ltd | Pharmaceuticals & Biotechnology | Large Cap | 6.04% |
| Apollo Hospitals Enterprises Ltd | Healthcare Services | Large Cap | 5.75% |
| Aurobindo Pharma Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 5.23% |
| Navin Fluorine International Ltd | Chemicals & Petrochemicals | Small Cap | 4.98% |
| Zydus Lifesciences Ltd | Pharmaceuticals & Biotechnology | Mid Cap | 4.97% |
| Aster Dm Healthcare Ltd | Healthcare Services | Mid Cap | 4.61% |
| Fortis Healthcare Ltd | Healthcare Services | Mid Cap | 3.77% |
Portfolio Allocation
Equity / Debt / Cash
Total Value
₹99 Cr
Market Cap Split
Total Value
100%
Equity sector allocation
Total Value
₹97 Cr
Exit load, stamp duty & tax
08-Feb-19
Nil upto 12% of units and 1% for remaining units on or before 90D, Nil after 90D
0.005% (from July 1st, 2020)
Taxation depends on the fund category and holding period. Consult the scheme document or a tax advisor for details.
Risk & Performance Ratios (1Y)
| Standard Deviation | -- |
| Beta | -- |
| Sharpe Ratio | -- |
| Sortino Ratio | -- |
| Treynor Ratio | -- |
| Jensen's Alpha | -- |
| Information Ratio | -- |
| R-Squared | -- |
| Max Drawdown | -- |
| Upside Capture | -- |
| Downside Capture | -- |
Fund management
Scheme Details
Investment objective
The Objective Of The Scheme Is To Achieve Long Term Capital Appreciation By Predominantly Investing In Equity And Equity Related Instruments Of Companies Engaged In Healthcare And Allied Sectors. However There Can Be No Assurance That The Investment Objective Under The Scheme Will Be Realized.
Fund house
LIC Mutual Fund Asset Management Limited
Frequently asked questions
What is the NAV of LIC MF Healthcare Fund-Direct Plan-Growth?
The NAV of LIC MF Healthcare Fund-Direct Plan-Growth is ₹34.62 as of 21 Oct 2026. NAV is updated at the end of every trading day.
How much expense ratio is charged by LIC MF Healthcare Fund-Direct Plan-Growth?
The expense ratio charged by LIC MF Healthcare Fund-Direct Plan-Growth is 1.37%.
What is the Min. SIP of LIC MF Healthcare Fund-Direct Plan-Growth?
The minimum SIP investment in LIC MF Healthcare Fund-Direct Plan-Growth is ₹200 per month.
What is the Min. Lumpsum of LIC MF Healthcare Fund-Direct Plan-Growth?
The minimum lumpsum investment in LIC MF Healthcare Fund-Direct Plan-Growth is ₹5,000.
What is the Exit Load of LIC MF Healthcare Fund-Direct Plan-Growth?
The exit load for LIC MF Healthcare Fund-Direct Plan-Growth is: Nil upto 12% of units and 1% for remaining units on or before 90D, Nil after 90D
.svg){kind=small}